Grufity logo
Grufity logo
TSHA

TSHA - Taysha Gene Therapies Inc Stock Price, Fair Value and News

$5.85-0.12 (-2.01%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

11/100

TSHA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

TSHA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TSHA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TSHA Price Action

Last 7 days

10.1%

Last 30 days

0.3%

Last 90 days

30.9%

Trailing 12 Months

135.4%

TSHA RSI Chart

TSHA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TSHA Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-13.21

Price/Sales (Trailing)

175.49

Price/Free Cashflow

-15.27

TSHA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TSHA Fundamentals

TSHA Revenue

Rev. Growth (Yr)

171.27%

Rev. Growth (Qtr)

-100%

TSHA Earnings

Earnings (TTM)

-129.9M

Earnings Growth (Yr)

-96.99%

Earnings Growth (Qtr)

-52.27%

TSHA Profitability

Return on Equity

-61.28%

Return on Assets

-43.24%

Free Cashflow Yield

-6.55%

TSHA Investor Care

Shares Dilution (1Y)

40.10%

Diluted EPS (TTM)

-0.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20257.2M8.1M6.3M9.8M
202414.2M12.9M9.9M8.3M
20235.7M9.0M12.2M15.5M
2022---2.5M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Taysha Gene Therapies Inc

TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
 CEO
 WEBSITEtayshagtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES65

Taysha Gene Therapies Inc Frequently Asked Questions

TSHA is the stock ticker symbol of Taysha Gene Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Taysha Gene Therapies Inc is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, TSHA's PE ratio (Price to Earnings) is -13.21 and Price to Sales (PS) ratio is 175.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSHA PE ratio will change depending on the future growth rate expectations of investors.